The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

Clinical trial NCT05085561 · COMPLETED

Trial details

NCT number: NCT05085561
Sponsor: Recursion Pharmaceuticals Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Cerebral Cavernous Malformation

Start date: 2022-03-17
Primary completion: 2025-06-30
Enrollment: 62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.